MedTrace Logo

Gut Microbiota and Cancer Immunotherapy Response

NCT04682327 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2021-08-13

No results posted yet for this study

Summary

This study will analyze the composition and diversity of the gut microbiota of patients with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) through metagenomic high-throughput sequencing methods, and explore the relationship between the gut microbiota and anti-PD-1/PD-L1 treatment response.

This study will further understand the influence and mechanism of the gut microbiota on tumor immunotherapy, and will provide new ideas and theoretical basis for improving the efficacy of tumor immunotherapy by targeting the gut microbiota in the clinic, and benefit more NSCLC patients.

Conditions

Interventions

OTHER

Response to anti-PD-1/PD-L1

Response to anti-PD-1/PD-L1, after 4 cycles of anti-PD-1/PD-L1 treatment.

OTHER

Non-response to anti-PD-1/PD-L1

Non response to anti-PD-1/PD-L1, after 4 cycles of anti-PD-1/PD-L1 treatment.

Sponsors & Collaborators

  • Shanghai Zhongshan Hospital

    lead OTHER

Principal Investigators

  • Xizhong Shen, MD, PhD · Fudan University

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-12
Primary Completion
2022-12-30
Completion
2022-12-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04682327 on ClinicalTrials.gov